Prognosis and mortality of polymyositis and dermatomyositis patients
- PMID: 16477398
- DOI: 10.1007/s10067-005-1164-z
Prognosis and mortality of polymyositis and dermatomyositis patients
Abstract
The objective of this study was to assess the long-term outcome of polymyositis (PM) and dermatomyositis (DM) and the factors predictive of this outcome in a nationwide series in Finland. One hundred and seventy-six patients with PM and 72 patients with DM diagnosed in Finland in 1969-1985 were selected from the national hospital discharge register according to the diagnostic criteria of Bohan and Peter and followed up until death or till the end of August 1995. Gender, age, delay of therapy, serum creatine kinase, erythrocyte sedimentation rate, initial dose of corticosteroids and duration of cytostatic therapy were assessed as factors prognostic of death. The 5-year survival rate for PM was 75% [95% confidence interval (CI): 68-81%] and that for DM 63% (50-73%), and the respective 10-year survival rates were 55% (47-62%) and 53% (41-64%). The median survival for polymyositis was 11.0 years (95% CI: 9.5-13.3) and that for DM 12.3 years (5.5-20.7). The standardized mortality ratio for the combined group of PM and DM showed approximately threefold mortality compared to the general population. Compared to PM patients, the subjects with DM had a 1.47-fold (95% CI: 0.99-2.12) age- and sex-adjusted risk of mortality. Except for age in both groups and the delay in diagnosis in the PM group, no other individual factor reached significance as a predictor of death. However, cancer had a hazard ratio (HR) of 2.16 for death (95% CI: 0.95-4.50) in the DM group and 1.99 (95% CI: 1.01-3.94) in the PM group. A comparison of the causes of death in the PM and DM groups showed that the patients with DM had a greater risk of dying from cancer (age-adjusted HR 5.11, 95% CI: 2.31-11.3). According to this nationwide analysis of survival and its prognostic factors in patients with PM and DM, the latter group had an increased age-adjusted risk for mortality compared to the former. The difference seems to be mostly explained by the fact that the patients with DM had a higher risk of dying from cancer.
Similar articles
-
Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors.Mod Rheumatol. 2016;26(1):115-20. doi: 10.3109/14397595.2015.1054081. Epub 2015 Jun 13. Mod Rheumatol. 2016. PMID: 26011440
-
Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study.Autoimmun Rev. 2014 Oct;13(10):1048-54. doi: 10.1016/j.autrev.2014.08.023. Epub 2014 Aug 23. Autoimmun Rev. 2014. PMID: 25183232
-
Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.J Rheumatol. 2001 Oct;28(10):2230-7. J Rheumatol. 2001. PMID: 11669162
-
Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis.Arthritis Rheum. 2009 Jan 15;61(1):108-18. doi: 10.1002/art.24372. Arthritis Rheum. 2009. PMID: 19116970 Review.
-
Hematological malignancy associated with polymyositis and dermatomyositis.Autoimmun Rev. 2012 Jul;11(9):615-20. doi: 10.1016/j.autrev.2011.10.024. Epub 2011 Oct 30. Autoimmun Rev. 2012. PMID: 22079677 Review.
Cited by
-
A Retrospective Review of Clinical Characteristics and Risk Factors of Dysphagia in Patients with Dermatomyositis.Dysphagia. 2024 Nov 8. doi: 10.1007/s00455-024-10763-6. Online ahead of print. Dysphagia. 2024. PMID: 39514083
-
Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis Without Cutaneous Findings or Rapidly Progressive Lung Disease: A Case Report.J Gen Intern Med. 2024 Oct;39(13):2595-2599. doi: 10.1007/s11606-024-08866-9. Epub 2024 Sep 16. J Gen Intern Med. 2024. PMID: 39285070 No abstract available.
-
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests.Rheumatology (Oxford). 2024 Jul 1;63(7):1825-1836. doi: 10.1093/rheumatology/keae029. Rheumatology (Oxford). 2024. PMID: 38230760 Free PMC article. Review.
-
Evolution of Seronegative Inflammatory Myositis to Dermatomyositis With Characteristic Cutaneous Features: A Case Report.J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231217829. doi: 10.1177/23247096231217829. J Investig Med High Impact Case Rep. 2023. PMID: 38097369 Free PMC article.
-
18F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study.Quant Imaging Med Surg. 2023 Jun 1;13(6):3522-3535. doi: 10.21037/qims-22-1174. Epub 2023 Mar 30. Quant Imaging Med Surg. 2023. PMID: 37284117 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
